Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program (QoliXane)
Non-interventional Study on Quality of Life, Efficacy and Tolerability of Nab-paclitaxel/Gemcitabine Firstline Therapy in Patients With Metastatic Pancreatic Cancer
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
A observational or N/A phase clinical study on Metastatic Pancreatic Cancer, this trial is completed. The trial is conducted by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest and has accumulated 14 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 9 earlier versions
-
May 2020 — Nov 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Sep 2019 — May 2020 [monthly]
Active Not Recruiting
-
Apr 2019 — Sep 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Recruiting NA
-
Aug 2017 — Feb 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Trium Analysis Online GmbH
- mca Berlin
For direct contact, visit the study record on ClinicalTrials.gov .